Cancer stem cells as mediators of treatment resistance in brain tumors: Status and controversies

Neoplasia

Volumn 9, Issue 11, 2007, Pages 882-892

  Sakariassen, Per Ø ^a   Immervoll, Heike ^a,b   Chekenya, Martha ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

CD133; Chemoresistance; Glioblastoma; Neural stem cell; Radioresistance

Indexed keywords

CD133 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; MESSENGER RNA;

BRAIN TUMOR; CANCER MORTALITY; CANCER RESISTANCE; CANCER STEM CELL; CANCER STEM CELL HYPOTHESIS; CANCER SURVIVAL; CARCINOGENIC ACTIVITY; CELL DIFFERENTIATION; CELL DIVISION; CELL SUBPOPULATION; GLIOBLASTOMA; HUMAN; HYPOTHESIS; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; RADIOSENSITIVITY; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; UNCERTAINTY; XENOGRAFT;

EID: 36048981199     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07658     Document Type: Article

References (97)

1. Russell DS and Rubinstein L (1989). Pathology of Tumours of the Central Nervous System Arnold, London.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987-996.
3. Zheng X, Shen G, Yang X, and Liu W (2007). Most C6 cells are cancer stem cells: evidence from clonal and population analyses. Cancer Res 67, 3691-3697.
4. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U, and Beier CP (2007). CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67, 4010-4015.
5. Hill RP (2006). Identifying cancer stem cells in solid tumors: case not proven. Cancer Res 66, 1891-1895 (discussion 1890).
6. Kleihus P and Scheithauer BW (1993). Histological Typing of Tumours of the Central Nervous System Springer-Verlag, New York.
7. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, and Cavenee WK (2002). The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61, 215-225 (discussion 226-229).
8. Mabron R, Svien HT, Hendrik J, Adson AW, and Kernohan JW (1950). Astrocytomas of the cerebellum. Arch Neurol Psychiatry 64(1), 74-88.
9. Doetsch F, Garcia-Verdugo JM, and Alvarez-Buylla A (1999). Regeneration of a germinal layer in the adult mammalian brain. Proc Natl Acad Sci USA 96, 11619-11624.
10. Bailey P and Cushing H (1926). A Classification of the Tumours of the Glioma Group on a Histogenetic Basis with a Correlated Study of Prognosis J.P. Lippincott, Philadelphia.
11. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, and Wahl GM (2006). Cancer stem cells - perspectives on current status and future directions: AACR Workshop on Cancer Stem Cells. Cancer Res 66, 9339-9344.
12. Kokkinakis DM, Watson ML, Honig LS, Rushing EJ, Mickey BE, Schold SC Jr (2001). Characterization of initiated cells in N-methylnitrosourea- induced carcinogenesis of the CNS in the adult rat. Neuro Oncol 3, 99-112.
13. Palmer TD, Takahashi J, and Gage FH (1997). The adult rat hippocampus contains primordial neural stem cells. Mol Cell Neurosci 8, 389-404.
14. Gould E, Tanapat P, McEwen BS, Flugge G, and Fuchs E (1998). Proliferation of granule cell precursors in the dentate gyrus of adult monkeys is diminished by stress. Proc Natl Acad Sci USA 95, 3168-3171.
15. Gould E, Reeves AJ, Graziano MS, and Gross CG (1999). Neurogenesis in the neocortex of adult primates. Science 286, 548-552.
16. Gage FH (1998). Stem cells of the central nervous system. Curr Opin Neurobiol 8, 671-676.
17. Shoshan Y, Nishiyama A, Chang A, Mork S, Barnett GH, Cowell JK, Trapp BD, and Staugaitis SM (1999). Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors. Proc Natl Acad Sci USA 96, 10361-10366.
18. Scolding NJ, Rayner PJ, and Compston DA (1999). Identification of A2B5-positive putative oligodendrocyte progenitor cells and A2B5-positive astrocytes in adult human white matter. Neuroscience 89, 1-4.
19. Scolding N, Franklin R, Stevens S, Heldin CH, Compston A, and Newcombe J (1998). Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis. Brain 121 (Pt 12), 2221-2228.
20. Sanai N, Tramontin AD, Quinones-Hinojosa A, Barbaro NM, Gupta N, Kunwar S, Lawton MT, McDermott MW, Parsa AT, Manuel-Garcia Verdugo J, et al. (2004). Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature 427, 740-744.
21. Nunes MC, Roy NS, Keyoung HM, Goodman RR, McKhann G II, Jiang L, Kang J, Nedergaard M, and Goldman SA (2003). Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain. Nat Med 9, 439-447.
22. Eriksson PS, Perfilieva E, Bjork-Eriksson T, Alborn AM, Nordborg C, Peterson DA, and Gage FH (1998). Neurogenesis in the adult human hippocampus. Nat Med 4, 1313-1317.
23. Levison SW, Young GM, and Goldman JE (1999). Cycling cells in the adult rat neocortex preferentially generate oligodendroglia. J Neurosci Res 57, 435-446.
24. Lantos PL and Pilkington GJ (1979). The development of experimental brain tumours. A sequential light and electron microscope study of the subependymal plate: I. Early lesions (abnormal cell clusters). Acta Neuropathol (Berl) 45, 167-175.
25. Silbergeld DL and Chicoine MR (1997). Isolation and characterization of human malignant glioma cells from histologically normal brain. J Neurosurg 86, 525-531.
26. Bonnet D and Dick JE (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3, 730-737.
27. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, Smith BD, Civin CI, and Jones RJ (2004). Characterization of clonogenic multiple myeloma cells. Blood 103, 2332-2336.
28. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, and Clarke MF (2003). Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100, 3983-3988.
29. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti MA, and Daidone MG (2005). Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65, 5506-5511.
30. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, and Dirks PB (2004). Identification of human brain tumour initiating cells. Nature 432, 396-401.
31. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, and De Maria R (2007). Identification and expansion of human colon-cancer-initiating cells. Nature 445, 111-115.
32. O'Brien CA, Pollett A, Gallinger S, and Dick JE (2007). A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106-110.
33. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, and Dirks PB (2003). Identification of a cancer stem cell in human brain tumors. Cancer Res 63, 5821-5828.
34. Bachoo RM, Maher EA, Ligon KL, Sharpless NE, Chan SS, You MJ, Tang Y, DeFrances J, Stover E, Weissleder R, et al. (2002). Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1, 269-277.
35. Diehn M and Clarke MF (2006). Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst 98, 1755-1757.
36. Wicha MS, Liu S, and Dontu G (2006). Cancer stem cells: an old idea - a paradigm shift. Cancer Res 66, 1883-1890 (discussion 1895-1896).
37. Fargeas CA, Huttner WB, and Corbeil D (2007). Nomenclature of prominin-1 (CD133) splice variants - an update. Tissue Antigens 69, 602-606.
38. Hewitt HB, Blake E, and Proter EH (1973). The effect of lethally irradiated cells on the transplantability of murine tumours. Br J Cancer 28, 123-135.
39. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, et al. (2007). A perivascular niche for brain tumor stem cells. Cancer Cell 11, 69-82.
40. Levine JM and Card JP (1987). Light and electron microscopic localization of a cell surface antigen (NG2) in the rat cerebellum: association with smooth protoplasmic astrocytes. J Neurosci 7, 2711-2720.
41. Horner PJ, Thallmair M, and Gage FH (2002). Defining the NG2-expressing cell of the adult CNS. J Neurocytol 31, 469-480.
42. Horner PJ, Power AE, Kempermann G, Kuhn HG, Palmer TD, Winkler J, Thal LJ, and Gage FH (2000). Proliferation and differentiation of progenitor cells throughout the intact adult rat spinal cord. J Neurosci 20, 2218-2228.
43. Chang A, Nishiyama A, Peterson J, Prineas J, and Trapp BD (2000). NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J Neurosci 20, 6404-6412.
44. Reynolds R, Dawson M, Papadopoulos D, Polito A, Di Bello IC, Pham-Dinh D, and Levine J (2002). The response of NG2-expressing oligodendrocyte progenitors to demyelination in MOG-EAE and MS. J Neurocytol 31, 523-536.
45. Levine JM and Stallcup WB (1987). Plasticity of developing cerebellar cells in vitro studied with antibodies against the NG2 antigen. J Neurosci 7, 2721-2731.
46. Levine JM and Nishiyama A (1996). The NG2 chondroitin sulfate proteoglycan: a multifunctional proteoglycan associated with immature cells. Perspect Dev Neurobiol 3, 245-259.
47. Reynolds R and Hardy R (1997). Oligodendroglial progenitors labeled with the O4 antibody persist in the adult rat cerebral cortex in vivo. J Neurosci Res 47, 455-470.
48. + glial cells are distinct from resting and activated microglia. J Neurosci Res 48, 299-312.
49. Nishiyama A, Watanabe M, Yang Z, and Bu J (2002). Identity, distribution, and development of polydendrocytes: NG2-expressing glial cells. J Neurocytol 31, 437-455.
50. Butt AM, Kiff J, Hubbard P, and Berry M (2002). Synantocytes: new functions for novel NG2 expressing glia. J Neurocytol 31, 551-565.
51. Berry M, Hubbard P, and Butt AM (2002). Cytology and lineage of NG2-positive glia. J Neurocytol 31, 457-467.
52. Dawson MR, Levine JM, and Reynolds R (2000). NG2-expressing cells in the central nervous system: are they oligodendroglial progenitors? J Neurosci Res 61, 471-479.
53. Dayer AG, Cleaver KM, Abouantoun T, and Cameron HA (2005). New GABAergic interneurons in the adult neocortex and striatum are generated from different precursors. J Cell Biol 168, 415-427.
54. Belachew S, Chittajallu R, Aguirre AA, Yuan X, Kirby M, Anderson S, and Gallo V (2003). Postnatal NG2 proteoglycan-expressing progenitor cells are intrinsically multipotent and generate functional neurons. J Cell Biol 161, 169-186.
55. Sellers DL and Horner PJ (2005). Instructive niches: environmental instructions that confound NG2 proteoglycan expression and the fate-restriction of CNS progenitors. J Anat 207, 727-734.
56. Dore-Duffy P, Katychev A, Wang X, and Van Buren E (2006). CNS microvascular pericytes exhibit multipotential stem cell activity. J Cereb Blood Flow Metab 26, 613-624.
57. Aguirre AA, Chittajallu R, Belachew S, and Gallo V (2004). NG2-expressing cells in the subventricular zone are type C-like cells and contribute to interneuron generation in the postnatal hippocampus. J Cell Biol 165, 575-589.
58. Aguirre A and Gallo V (2004). Postnatal neurogenesis and gliogenesis in the olfactory bulb from NG2-expressing progenitors of the subventricular zone. J Neurosci 24, 10530-10541.
59. Fang X, Burg MA, Barritt D, Dahlin-Huppe K, Nishiyama A, and Stallcup WB (1999). Cytoskeletal reorganization induced by engagement of the NG2 proteoglycan leads to cell spreading and migration. Mol Biol Cell 10, 3373-3387.
60. Burg MA, Grako KA, and Stallcup WB (1998). Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells. J Cell Physiol 177, 299-312.
61. Wolswijk G and Noble M (1989). Identification of an adult-specific glial progenitor cell. Development 105, 387-400.
62. Ffrench-Constant C and Raff MC (1986). Proliferating bipotential glial progenitor cells in adult rat optic nerve. Nature 319, 499-502.
63. Spassky N, Goujet-Zalc C, Parmantier E, Olivier C, Martinez S, Ivanova A, Ikenaka K, Macklin W, Cerruti I, Zalc B, et al. (1998). Multiple restricted origin of oligodendrocytes. J Neurosci 18, 8331-8343.
64. Temple S and Alvarez-Buylla A (1999). Stem cells in the adult mammalian central nervous system. Curr Opin Neurobiol 9, 135-141.
65. Alvarez-Buylla A and Temple S (1998). Stem cells in the developing and adult nervous system. J Neurobiol 36, 105-110.
66. Thallmair M, Ray J, Stallcup WB, and Gage FH (2006). Functional and morphological effects of NG2 proteoglycan deletion on hippocampal neurogenesis. Exp Neurol 202, 167-178.
67. Chekenya M, Rooprai HK, Davies D, Levine JM, Butt AM, and Pilkington GJ (1999). The NG2 chondroitin sulfate proteoglycan: role in malignant progression of human brain tumours. Int J Dev Neurosci 17, 421-435.
68. Barnett SC, Robertson L, Graham D, Allan D, and Rampling R (1998). Oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells transformed with c-myc and H-ras form high-grade glioma after stereotactic injection into the rat brain. Carcinogenesis 19, 1529-1537.
69. Noble M, Gutowski N, Bevan K, Engel U, Linskey M, Urenjak J, Bhakoo K, and Williams S (1995). From rodent glial precursor cell to human glial neoplasia in the oligodendrocyte-type-2 astrocyte lineage. Glia 15, 222-230.
70. Watanabe K, Nagai M, Wakai S, Arai T, and Kawashima K (1990). Loss of constitutional heterozygosity in chromosome 10 in human glioblastoma. Acta Neuropathol (Berl) 80, 251-254.
71. Rasheed BK, Fuller GN, Friedman AH, Bigner DD, and Bigner SH (1992). Loss of heterozygosity for 10q loci in human gliomas. Genes Chromosomes Cancer 5, 75-82.
72. Fults D, Brockmeyer D, Tullous MW, Pedone CA, and Cawthon RM (1992). p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. Cancer Res 52, 674-679.
73. Mao X, Jones TA, Tomlinson I, Rowan AJ, Fedorova LI, Zelenin AV, Mao JI, Gutowski NJ, Noble M, and Sheer D (1999). Genetic aberrations in glioblastoma multiforme: translocation of chromosome 10 in an O-2A-like cell line. Br J Cancer 79, 724-731.
74. Clarke MF (2005). A self-renewal assay for cancer stem cells. Cancer Chemother Pharmacol 56 (Suppl 1), 64-68.
75. Berns A (2005). Stem cells for lung cancer? Cell 121, 811-813.
76. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, and Rich JN (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760.
77. + breast cancer-initiating cells to radiation. J Natl Cancer Inst 98, 1777-1785.
78. Liu G, Black KL, and Yu JS (2006). Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination. Expert Rev Vaccines 5, 233-247.
79. Hambardzumyan D, Squatrito M, and Holland EC (2006). Radiation resistance and stem-like cells in brain tumors. Cancer Cell 10, 454-456.
80. + sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 67, 1-5.
81. Bergmann M, Romirer I, Sachet M, Fleischhacker R, Garcia-Sastre A, Palese P, Wolff K, Pehamberger H, Jakesz R, and Muster T (2001). A genetically engineered influenza A virus with ras-dependent oncolytic properties. Cancer Res 61, 8188-8193.
82. Peacock CD, Wang Q, Gesell GS, Corcoran-Schwartz IM, Jones E, Kim J, Devereux WL, Rhodes JT, Huff CA, Beachy PA, et al. (2007). Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci USA 104, 4048-4053.
83. Cheng T (2004). Cell cycle inhibitors in normal and tumor stem cells. Oncogene 23, 7256-7266.
84. Shah K, Bureau E, Kim DE, Yang K, Tang Y, Weissleder R, and Breakefield XO (2005). Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Ann Neurol 57, 34-41.
85. Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, Small JE, Herrlinger U, Ourednik V, Black PM, et al. (2000). Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA 97, 12846-12851.
86. Benedetti S, Pirola B, Pollo B, Magrassi L, Bruzzone MG, Rigamonti D, Galli R, Selleri S, Di Meco F, De Fraja C, et al. (2000). Gene therapy of experimental brain tumors using neural progenitor cells. Nat Med 6, 447-450.
87. Ehtesham M, Kabos P, Kabosova A, Neuman T, Black KL, and Yu JS (2002). The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res 62, 5657-5663.
88. Kim SK, Cargioli TG, Machluf M, Yang W, Sun Y, Al-Hashem R, Kim SU, Black PM, and Carroll RS (2005). PEX-producing human neural stem cells inhibit tumor growth in a mouse glioma model. Clin Cancer Res 11, 5965-5970.
89. Vescovi AL, Galli R, and Reynolds BA (2006). Brain tumour stem cells. Nat Rev Cancer 6, 425-436.
90. Niki T, Iba S, Tokunou M, Yamada T, Matsuno Y, and Hirohashi S (2000). Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res 6, 2431-2439.
91. Leon SP, Folkerth RD, and Black PM (1996). Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 77, 362-372.
92. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, et al. (2001). A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95, 190-198.
93. Hammoud MA, Sawaya R, Shi W, Thall PF, and Leeds NE (1996). Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol 27, 65-73.
94. Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW, Ghivizzani SC, Ignatova TN, and Steindler DA (2005). Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 7, 967-976.
95. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, and Herlyn M (2005). A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65, 9328-9337.
96. Xin L, Lawson DA, and Witte ON (2005). The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci USA 102, 6942-6947.
97. Collins AT, Berry PA, Hyde C, Stower MJ, and Maitland NJ (2005). Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65, 10946-10951.